NCT03129139View on ClinicalTrials.gov

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

June 1, 2024

Study Completion Date

December 1, 2024

Conditions
Advanced CancerGastric CancerBreast CancerPancreatic CancerProstate Cancer MetastaticColo-rectal CancerSolid TumorSolid CarcinomaSolid Carcinoma of StomachCancer of Stomach
Interventions
DRUG

Minnelide™Capsules

Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.

Trial Locations (7)

27157

RECRUITING

Wake Forest Baptist Health, Winston-Salem

32224

TERMINATED

Mayo Clinic, Jacksonville

35249

RECRUITING

University of Alabama at Birmingham, Birmingham

55905

TERMINATED

Mayo Clinic, Rochester

85054

WITHDRAWN

Mayo Clinic Arizona, Phoenix

85258

RECRUITING

HonorHealth Research Institute, Scottsdale

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Translational Drug Development

OTHER

lead

Minneamrita Therapeutics LLC

INDUSTRY

NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter